Evidence map›Paper›PMID 42332684›Full record

Observational studyBMC medicine2026

Matrigel/serum-free, high-fidelity patient-derived tumor-like cell clusters as an in vitro platform for large-scale compound screening and chemoresistance prediction in oral cancer.

Yufeng Luo, Jiawen Li, Shang Xie, Shenyi Yin, Juan Li, Junxuan Zhao, Ying Sun, Renzhi Qian, Xinyu He, Feixiang Ge and 10 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yufeng Luo *Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
Jiawen Li *Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, 100081, China.
Shang Xie *Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, 100081, China.
Shenyi YinGeneX Health Co. Ltd, Beijing, 100195, China.
Juan LiDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
Junxuan ZhaoDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
Ying SunAcademy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Renzhi QianDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
Xinyu HeDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
Feixiang GeDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
Zhiqing XiaoDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
Yi SuiDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, 100081, China.
Luming WangDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, 100081, China.
Hao YuAcademy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Huinan LuPeking University Yangtze Center of Future Health Technology, Wuxi, 214111, China.
Hanshuo ZhangGeneX Health Co. Ltd, Beijing, 100195, China.
Buqing YeDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
Xiaofeng ShanDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, 100081, China. kqsxf@bjmu.edu.cn.
Zhigang CaiDepartment of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, 100081, China. czg4209@126.com.
Jianzhong Jeff XiDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China. jzxi@pku.edu.cn.

Funding

Basic Science Center Program of the National Natural Science Foundation of China No. T2288102Beijing Life Science Academy No.2025600CB0050Clinical New Technology and New Therapy Project of Peking University School of Stomatology PKUSSNCT-23B05National Key Research and Development Program of China No. 2022YFC2504200National Key Research and Development Program of China No. 2024YFF0507401National Natural Science Foundation of China No. 82372885
6 · The paper itself

Abstract

backgroundCurrent drug regimens for oral cancer are primarily based on generalized clinical guidelines, lacking a precision medicine strategy to tailor therapies to individual patients. This gap highlights the need for robust humanized models that can accurately reflect tumor characteristics and guide personalized treatment selection.

methodsWe developed patient-derived tumor-like cell clusters (PTCs) for oral cancer, an ex vivo model designed to preserve key tumor features including the immune microenvironment, phenotype, and genotype. Then, a prospective observational clinical validation study (ChiCTR2300075543) was conducted in 42 patients with advanced oral squamous cell carcinoma (OSCC) to evaluate the utility of PTC-guided sensitivity testing for the TPF neoadjuvant chemotherapy regimen (docetaxel, cisplatin, fluorouracil). Additionally, the PTC platform was utilized for high-throughput drug screening, and transcriptomic analysis was performed to identify potential predictive biomarkers.

resultsPTCs were generated with a success rate exceeding 97% (161/165) using minimal tissue samples (≥ 10 mg). PTC-guided sensitivity testing for the TPF regimen showed ~90% (34/38) concordance with clinical outcomes in advanced OSCC patients. Moreover, the PTC platform successfully enabled high-throughput drug screening (> 100 compounds within two weeks), facilitating the identification of novel anti-cancer targets. Specifically, transcriptomic analysis revealed that upregulation of MMP13 is highly associated with treatment resistance (Pearson's r = 0.90, P < 0.01).

conclusionsOur PTC-based platform robustly preserves critical tumor characteristics and demonstrates high concordance with clinical treatment outcomes, making it a valuable tool for selecting personalized therapies in oral cancer. Its capacity for large-scale compound screening also supports novel anti-cancer target discovery. Furthermore, MMP13 emerges as a potential predictive biomarker for treatment resistance. Collectively, this PTC platform represents a transformative precision medicine approach to advance personalized therapy and drug discovery in oral cancer.

trial registrationClinicalTrials.gov Identifier: ChiCTR2300075543; registered prospectively on September 7, 2023.

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellDrug Resistance, NeoplasmMouth NeoplasmsAgedCollagenDrug Screening Assays, AntitumorFemaleHumansLamininMaleMiddle AgedProspective StudiesProteoglycansAntineoplastic AgentsCollagenLamininProteoglycansChemoresistance predictionDrug sensitivity testingMatrigel/serum-freeNeoadjuvant chemotherapyOral squamous cell carcinomaPatient-derived tumor-like cell clusters

Identifiers

PMID42332684
PMCPMC13548490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.